{"nctId":"NCT00494507","briefTitle":"Hyper- and Hypokalemic Periodic Paralysis Study","startDateStruct":{"date":"2007-06"},"conditions":["Hyperkalemic Periodic Paralysis","Hypokalemic Periodic Paralysis"],"count":71,"armGroups":[{"label":"HYP Dichlorphenamide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dichlorphenamide (double-blind)","Drug: Dichlorphenamide (open-label)"]},{"label":"HYP Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (double-blind)","Drug: Dichlorphenamide (open-label)"]},{"label":"HOP Dichlorphenamide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dichlorphenamide (double-blind)","Drug: Dichlorphenamide (open-label)"]},{"label":"HOP Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (double-blind)","Drug: Dichlorphenamide (open-label)"]}],"interventions":[{"name":"Dichlorphenamide (double-blind)","otherNames":["Daranide"]},{"name":"Placebo (double-blind)","otherNames":[]},{"name":"Dichlorphenamide (open-label)","otherNames":["Daranide"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Genetically definite, clinically definite or clinically probable Hyperkalemic or Hypokalemic Periodic Paralysis as outlined in the protocol\n* Male and female participants, age 18 and older who are able to comply with the study conditions.\n* Participants who have distinct regular episodes of weakness with an average frequency of \\> or = to 1 a week and \\< or = to 3 a day either on or off treatment, whichever is higher\n* Normal thyroid-stimulating hormone (TSH) level\n\nExclusion Criteria:\n\n* Evidence for Andersen-Tawil syndrome (any one of the following 3 criteria)\n\n  1. Prolonged QT interval or complex ventricular ectopy between attacks\n  2. Distinctive physical features (2 of the following 5)\n\n     1. Low set ears\n     2. Short stature\n     3. Hypo-/micrognathia\n     4. Clinodactyly\n     5. Hypo-/hypertelorism\n  3. KIR 2.1 gene mutation\n* Coincidental renal, hepatic, active thyroid disease, restrictive or obstructive lung disease, other neuromuscular disease, or heart disease\n* Chronic, non-congestive, angle-closure glaucoma\n* Use of any of the following medications for reasons other than treatment of periodic paralysis: diuretics, antiarrhythmics, corticosteroids, beta-blockers, calcium channel blockers, antiepileptics, magnesium\n* History of life-threatening episodes of respiratory muscle weakness or cardiac arrhythmias during attacks\n* Pregnancy\n* Known mutation in the alpha subunit of the sodium channel gene in hypokalemic periodic paralysis patients","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HYP Attack Rate","description":"The number of distinct attacks per week over the final 8 weeks (Weeks 2-9) of the double-blind treatment period as self-reported by HYP participants.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]}]},{"type":"PRIMARY","title":"HOP Attack Rate","description":"The number of distinct attacks per week over the final 8 weeks (Weeks 2-9) of the double-blind treatment period as self-reported by HOP participants.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]}]},{"type":"SECONDARY","title":"HYP Severity-weighted Attack Rate","description":"HYP participant severity-weighted attack rate is defined as the sum of average attack severity across all distinct attacks over the final 8 weeks (Weeks 2-9) of the double-blind treatment period divided by the number of weeks that the subject was followed. Attack severity (scored as 1-10 with increasing severity) is self-reported.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]}]},{"type":"SECONDARY","title":"HOP Severity-weighted Attack Rate","description":"HOP participant severity-weighted attack rate is defined as the sum of average attack severity across all distinct attacks over the final 8 weeks (Weeks 2-9) of the double-blind treatment period divided by the number of weeks that the subject was followed. Attack severity (scored as 1-10 with increasing severity) is self-reported.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"HYP Attack Duration","description":"HYP participant total attack duration per week, defined as the sum of attack durations across all distinct attacks over the final 8 weeks (Weeks 2-9) of the double-blind treatment period divided by the number of weeks that the subject was followed.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null},{"groupId":"OG001","value":"39.4","spread":null}]}]}]},{"type":"SECONDARY","title":"HOP Attack Duration","description":"HOP participant total attack duration per week, defined as the sum of attack durations across all distinct attacks over the final 8 weeks (Weeks 2-9) of the double-blind treatment period divided by the number of weeks that the subject was followed.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"26.2","spread":null}]}]}]},{"type":"SECONDARY","title":"HYP Endpoint of Acute Worsening","description":"Increase in attack frequency or severity in HYP participants necessitating withdrawal from the initial nine-week double-blind treatment period and moving directly into the open-label phase.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"HOP Endpoint of Acute Worsening","description":"Increase in attack frequency or severity in HOP participants necessitating withdrawal from the initial nine-week double-blind treatment period and moving directly into the open-label phase.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"HYP Change From Baseline to Week 9 in Average Manual Muscle Testing (MMT) Score","description":"The strength of each of 26 individual muscles was graded using a modified 13-point Medical Research Council scale ranging from 0-5. Recorded grades were converted to numerical values as follows prior to averaging across muscles to form a composite score: 0 = 0; 1 = 1; 2- = 1.67; 2 = 2; 2+ = 2.33; 3- = 2.67; 3 = 3; 3+ = 3.33; 4- = 3.67; 4 = 4; 4+ = 4.33; 5- = 4.67; 5 = 5. A higher score represents a better outcome, i.e. 5 = normal strength.\n\nThe following muscles were tested: shoulder abductor (left/right), elbow extensor (left/right), elbow flexor (left/right), wrist extensor (left/right), wrist flexor (left/right), hip flexor (left/right), hip extensor (left/right), hip abductor (left/right), knee extensor (left/right), knee flexor (left/right), ankle dorsiflexor (left/right), ankle plantar flexor (left/right), neck extensor, neck flexor.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.26"},{"groupId":"OG001","value":"0.00","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"HOP Change From Baseline to Week 9 in Average Manual Muscle Testing (MMT) Score","description":"The strength of each of 26 individual muscles was graded using a modified 13-point Medical Research Council scale ranging from 0-5. Recorded grades were converted to numerical values as follows prior to averaging across muscles to form a composite score: 0 = 0; 1 = 1; 2- = 1.67; 2 = 2; 2+ = 2.33; 3- = 2.67; 3 = 3; 3+ = 3.33; 4- = 3.67; 4 = 4; 4+ = 4.33; 5- = 4.67; 5 = 5. A higher score represents a better outcome, i.e. 5 = normal strength.\n\nThe following muscles were tested: shoulder abductor (left/right), elbow extensor (left/right), elbow flexor (left/right), wrist extensor (left/right), wrist flexor (left/right), hip flexor (left/right), hip extensor (left/right), hip abductor (left/right), knee extensor (left/right), knee flexor (left/right), ankle dorsiflexor (left/right), ankle plantar flexor (left/right), neck extensor, neck flexor.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.21"},{"groupId":"OG001","value":"-0.08","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"HYP Change From Baseline to Week 9 in Average Maximum Voluntary Isometric Contraction Testing (MVICT) Scores","description":"The strength of each of 10 muscles was measured using quantitative myometry and expressed as the number of standard deviations from normal (Z-score) given the participant's age, gender, and height. The scores were averaged across muscles to form a composite MVICT score: average standardized MVICT score. A positive Z-score indicates a better outcome.\n\nThe following muscles were tested: elbow extensor (left/right), elbow flexor (left/right), knee extensor (left/right), knee flexor (left/right), and hand grip (left/right).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"0.52"},{"groupId":"OG001","value":"0.55","spread":"0.76"}]}]}]},{"type":"SECONDARY","title":"HOP Change From Baseline to Week 9 in Average Maximum Voluntary Isometric Contraction Testing (MVICT) Scores","description":"The strength of each of 10 muscles was measured using quantitative myometry and expressed as the number of standard deviations from normal (Z-score) given the participant's age, gender, and height. The scores were averaged across muscles to form a composite MVICT score: average standardized MVICT score. A positive Z-score indicates a better outcome.\n\nThe following muscles were tested: elbow extensor (left/right), elbow flexor (left/right), knee extensor (left/right), knee flexor (left/right), and hand grip (left/right).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.92"},{"groupId":"OG001","value":"-0.27","spread":"0.58"}]}]}]},{"type":"SECONDARY","title":"HYP Change From Baseline to Week 9 in Average Maximum Voluntary Isometric Contraction Testing Percent of Predicted Normal","description":"The strength of each of 10 muscles was measured using quantitative myometry and expressed as the percent of predicted normal given the participant's age, gender, and height. The scores were averaged across muscles to form a composite MVICT score: average percent of predicted normal score. A higher number indicates a better outcome.\n\nThe following muscles were tested: elbow extensor (left/right), elbow flexor (left/right), knee extensor (left/right), knee flexor (left/right), and hand grip (left/right).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.84","spread":"8.27"},{"groupId":"OG001","value":"10.17","spread":"14.54"}]}]}]},{"type":"SECONDARY","title":"HOP Change From Baseline to Week 9 in Average Maximum Voluntary Isometric Contraction Testing Percent of Predicted Normal","description":"The strength of each of 10 muscles was measured using quantitative myometry and expressed as the percent of predicted normal given the participant's age, gender, and height. The scores were averaged across muscles to form a composite MVICT score: average percent of predicted normal score. A higher number indicates a better outcome.\n\nThe following muscles were tested: elbow extensor (left/right), elbow flexor (left/right), knee extensor (left/right), knee flexor (left/right), and hand grip (left/right).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.81","spread":"11.27"},{"groupId":"OG001","value":"-2.94","spread":"7.20"}]}]}]},{"type":"SECONDARY","title":"HYP Change From Baseline to Week 9 in Lean Body Mass","description":"Lean body mass was measured by dual-energy X-ray absorptiometry (DEXA).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.31","spread":"1.94"},{"groupId":"OG001","value":"-1.52","spread":"1.47"}]}]}]},{"type":"SECONDARY","title":"HOP Change From Baseline to Week 9 in Lean Body Mass","description":"Lean body mass was measured by dual-energy X-ray absorptiometry (DEXA).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"1.65"},{"groupId":"OG001","value":"0.44","spread":"2.39"}]}]}]},{"type":"SECONDARY","title":"HYP Change From Baseline to Week 9 in SF-36 Physical Component Summary Score","description":"The Medical Outcomes Study Short Form (SF-36) questionnaire is a widely used profile measure of generic health-related quality of life. The 36 questions are allocated to eight scales: physical function (PF), physical role (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social function (SF), mental health (MH), and emotional role (RE). The physical component summary score is calculated from the four scales of PF, RP,BP, and GH. Scores are constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. Higher scores are associated with better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.16","spread":"7.84"},{"groupId":"OG001","value":"-0.11","spread":"7.82"}]}]}]},{"type":"SECONDARY","title":"HOP Change From Baseline to Week 9 in SF-36 Physical Component Summary Score","description":"The Medical Outcomes Study Short Form (SF-36) questionnaire is a widely used profile measure of generic health-related quality of life. The 36 questions are allocated to eight scales: physical function (PF), physical role (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social function (SF), mental health (MH), and emotional role (RE). The physical component summary score is calculated from the four scales of PF, RP, BP, and GH. Scores are constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. Higher scores are associated with better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.83","spread":"7.23"},{"groupId":"OG001","value":"-3.75","spread":"10.61"}]}]}]},{"type":"SECONDARY","title":"HYP Change From Baseline to Week 9 in SF-36 Mental Health Component Summary Score","description":"The Medical Outcomes Study Short Form (SF-36) questionnaire is a widely used profile measure of generic health-related quality of life. The 36 questions are allocated to eight scales: physical function (PF), physical role (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social function (SF), mental health (MH), and emotional role (RE). The mental health component summary score is calculated from the four scales of VT, SF, MH, and RE. Scores are constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. Higher scores are associated with better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.77","spread":"14.09"},{"groupId":"OG001","value":"2.65","spread":"8.64"}]}]}]},{"type":"SECONDARY","title":"HOP Change From Baseline to Week 9 in SF-36 Mental Health Component Summary Score","description":"The Medical Outcomes Study Short Form (SF-36) questionnaire is a widely used profile measure of generic health-related quality of life. The 36 questions are allocated to eight scales: physical function (PF), physical role (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social function (SF), mental health (MH), and emotional role (RE). The mental health component summary score is calculated from the four scales of VT, SF, MH, and RE. Scores are constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. Higher scores are associated with better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.10","spread":"9.93"},{"groupId":"OG001","value":"-5.65","spread":"12.58"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":12},"commonTop":["PARAESTHESIA","COGNITIVE DISORDER","DYSGEUSIA","FALL","HEADACHE"]}}}